p38ß (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models
[Background and purpose]: Gemcitabine is an antitumour agent currently used in the treatment of several types of cancer with known properties as a radiosensitizer. p38MAPK signalling pathway has been shown to be a major determinant in the cellular response to gemcitabine in different experimental mo...
| Autores: | , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión aceptada para publicación |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/242101 |
| Acceso en línea: | http://hdl.handle.net/10261/242101 |
| Access Level: | acceso abierto |
| Palabra clave: | Gemcitabine, p38MAPK MAPK11 (p38β) MAPK14 (p38α) Radiosensitivity Sarcoma |
| Sumario: | [Background and purpose]: Gemcitabine is an antitumour agent currently used in the treatment of several types of cancer with known properties as a radiosensitizer. p38MAPK signalling pathway has been shown to be a major determinant in the cellular response to gemcitabine in different experimental models. However, the molecular mechanism implicated in gemcitabine-associated radiosensitivity remains unknown. |
|---|